Kinetics of CD19 B-cell depletion post-rituximab in membranous nephropathy.
作者信息
Sevinc Mustafa, Shukkur Meshaal, Hamilton Patrick, Thet May, Bate Sebastian, Ragy Omar, Kanigicherla Durga A K
机构信息
Manchester Institute of Nephrology and Transplantation, Renal Department, Manchester, UK.
Manchester University NHS Foundation Trust, Medicine Department, Manchester, UK.
出版信息
Clin Kidney J. 2025 May 19;18(6):sfaf153. doi: 10.1093/ckj/sfaf153. eCollection 2025 Jun.
Abstract
摘要
相似文献
1
Kinetics of CD19 B-cell depletion post-rituximab in membranous nephropathy.利妥昔单抗治疗膜性肾病后CD19 B细胞耗竭的动力学
Clin Kidney J. 2025 May 19;18(6):sfaf153. doi: 10.1093/ckj/sfaf153. eCollection 2025 Jun.
2
Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.奥妥珠单抗对利妥昔单抗难治性磷脂酶A2受体相关膜性肾病的治疗有效。
Clin Kidney J. 2025 May 1;18(5):sfaf026. doi: 10.1093/ckj/sfaf026. eCollection 2025 May.
3
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.高剂量利妥昔单抗治疗 PLA2R1 相关膜性肾病的早期缓解作用。
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182. doi: 10.2215/CJN.11791018. Epub 2019 Jul 24.
4
Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings?分子标志物还是临床终点？在资源有限的环境中，膜性肾病患者使用低剂量利妥昔单抗时，最佳监测工具是什么？
J Nephrol. 2025 Jul;38(6):1717-1719. doi: 10.1007/s40620-025-02273-x. Epub 2025 Apr 7.
5
Low risk of hepatitis B virus reactivation in membranous nephropathy patients with resolved infection undergoing rituximab-based regimens without antiviral prophylaxis.在未接受抗病毒预防的情况下，接受利妥昔单抗为基础的方案治疗的感染已解决的膜性肾病患者中，乙型肝炎病毒再激活的风险较低。
Int Immunopharmacol. 2024 Sep 30;139:112731. doi: 10.1016/j.intimp.2024.112731. Epub 2024 Jul 27.
6
Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology.肾脏病学中单剂低剂量利妥昔单抗的临床应答和 B 细胞抑制模式。
Kidney360. 2020 Apr 2;1(5):359-367. doi: 10.34067/KID.0000072020. eCollection 2020 May 28.
7
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.奥妥珠单抗和奥法木单抗在治疗伴有抗利妥昔单抗抗体的膜性肾病患者方面比利妥昔单抗更有效。
Kidney Int Rep. 2024 Dec 17;10(3):753-761. doi: 10.1016/j.ekir.2024.12.012. eCollection 2025 Mar.
8
The Efficacy of Rituximab in the Treatment of Membranous Nephropathy.利妥昔单抗治疗膜性肾病的疗效。
J Nepal Health Res Counc. 2021 Jan 21;18(4):580-587. doi: 10.33314/jnhrc.v18i4.2481.
9
A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.一名患有 semaphorin 3b 相关膜性肾病的儿童在利妥昔单抗耐药后用奥滨尤妥珠单抗治疗有效。
Pediatr Nephrol. 2024 Jan;39(1):305-308. doi: 10.1007/s00467-023-06085-8. Epub 2023 Jul 19.
10
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.每月小剂量利妥昔单抗治疗原发性抗 PLA2R 阳性膜性肾病：一种个体化方法。
BMC Nephrol. 2023 May 26;24(1):146. doi: 10.1186/s12882-023-03206-1.
本文引用的文献
1
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
2
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.利妥昔单抗治疗特发性膜性肾病：一项为期 2 年的研究。
Clin J Am Soc Nephrol. 2010 Dec;5(12):2188-98. doi: 10.2215/CJN.05080610. Epub 2010 Aug 12.
3
Rituximab treatment of idiopathic membranous nephropathy.利妥昔单抗治疗特发性膜性肾病。
Kidney Int. 2008 Jan;73(1):117-25. doi: 10.1038/sj.ki.5002628. Epub 2007 Oct 17.
4
Rituximab for idiopathic membranous nephropathy.利妥昔单抗治疗特发性膜性肾病
Lancet. 2002 Sep 21;360(9337):923-4. doi: 10.1016/S0140-6736(02)11042-7.
Zotero 插件